KR20210088583A - 당뇨병 치료를 위한 펩타이드 단편 - Google Patents

당뇨병 치료를 위한 펩타이드 단편 Download PDF

Info

Publication number
KR20210088583A
KR20210088583A KR1020217014389A KR20217014389A KR20210088583A KR 20210088583 A KR20210088583 A KR 20210088583A KR 1020217014389 A KR1020217014389 A KR 1020217014389A KR 20217014389 A KR20217014389 A KR 20217014389A KR 20210088583 A KR20210088583 A KR 20210088583A
Authority
KR
South Korea
Prior art keywords
peptide
seq
formulation
agent
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217014389A
Other languages
English (en)
Korean (ko)
Inventor
잔 알렌폴
마리아 에크블라드
폰투스 듀너
Original Assignee
폴리쿰 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴리쿰 에이비 filed Critical 폴리쿰 에이비
Publication of KR20210088583A publication Critical patent/KR20210088583A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217014389A 2018-11-07 2019-11-07 당뇨병 치료를 위한 펩타이드 단편 Ceased KR20210088583A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204862 2018-11-07
EP18204862.9 2018-11-07
PCT/EP2019/080563 WO2020094797A1 (en) 2018-11-07 2019-11-07 Peptide fragments for treatment of diabetes

Publications (1)

Publication Number Publication Date
KR20210088583A true KR20210088583A (ko) 2021-07-14

Family

ID=64183928

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014389A Ceased KR20210088583A (ko) 2018-11-07 2019-11-07 당뇨병 치료를 위한 펩타이드 단편

Country Status (13)

Country Link
US (2) US20220002343A1 (https=)
EP (1) EP3876970A1 (https=)
JP (1) JP7553115B2 (https=)
KR (1) KR20210088583A (https=)
CN (1) CN113164548A (https=)
AU (1) AU2019374981A1 (https=)
BR (1) BR112021008888A2 (https=)
CA (1) CA3116612A1 (https=)
IL (1) IL282519A (https=)
MX (1) MX2021005386A (https=)
SG (1) SG11202104276YA (https=)
WO (1) WO2020094797A1 (https=)
ZA (1) ZA202102572B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218095A1 (en) * 2022-05-13 2023-11-16 Coegin Pharma Ab Agents for stimulating tissue regeneration
JP2025516717A (ja) * 2022-05-13 2025-05-30 コーギン ファーマ エービー 血管新生を誘発する薬剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505750A (ja) * 1994-09-16 1998-06-09 ザ スクリップス リサーチ インスティテュート 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
WO2004015390A2 (en) 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
US9044438B2 (en) * 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2114422A1 (en) * 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201406989D0 (en) * 2014-04-17 2014-06-04 Follicum Ab Novel treatments
CA3061935A1 (en) * 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes

Also Published As

Publication number Publication date
AU2019374981A1 (en) 2021-05-27
SG11202104276YA (en) 2021-05-28
BR112021008888A2 (pt) 2021-08-17
ZA202102572B (en) 2022-10-26
US20240327459A1 (en) 2024-10-03
CA3116612A1 (en) 2020-05-14
IL282519A (en) 2021-06-30
US20220002343A1 (en) 2022-01-06
WO2020094797A1 (en) 2020-05-14
JP2022516400A (ja) 2022-02-28
EP3876970A1 (en) 2021-09-15
MX2021005386A (es) 2021-07-06
JP7553115B2 (ja) 2024-09-18
CN113164548A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US10815283B2 (en) Peptides for treatment of diabetes
Westermark Amyloid and polypeptide hormones: what is their interrelationship?
CN100374461C (zh) 胰高血糖素样肽-2及其治疗应用
JPH05506427A (ja) 糖尿病治療に有用なｇｌｐ―１アナログ
US20240327459A1 (en) Peptide fragments for treatment of diabetes
US20150005233A1 (en) Treatment of hypoglycemia
TW200902068A (en) GLP-1 peptide having sugar chain attached thereto
US20100221240A1 (en) Chemically Modified Peptide Analogs
Lynch et al. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation
US20160002310A1 (en) Modified ingap peptides for treating diabetes
WO2011002673A1 (en) Leptin agonist and methods of use
HK40017988A (en) Peptides for treatment of diabetes
HK40017988B (en) Peptides for treatment of diabetes
DeFreest et al. REPORT DOCUMENTATION PAGE 0MB No. 074-0138
EP4171607A1 (en) Vasopressin-2 receptor antagonist peptides and uses thereof
BR112018007225B1 (pt) Agonista do receptor de glucagon, seu uso e composição farmacêutica

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601